## **Product Data Sheet**

#### APC/Fire™ 750 anti-human CD158e1 (KIR3DL1, NKB1)

Catalog # / 2163610 / 100 tests

**Size:** 2163605 / 25 tests

Clone: DX9

**Isotype:** Mouse IgG1, κ

Immunogen: Human NK cell clone VL186-1.6

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with

APC/Fire™ 750 under optimal


conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD56 PE and CD158e1 (clone DX9) APC/Fire™ 750 (top) or mouse IgG1, κ APC/Fire™ 750 isotype control (bottom).

### **Applications:**

**Applications:** Flow Cytometry

Recommended

**Usage:** 

Each lot of this antibody is quality control tested by immunofluorescent

staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per

100  $\mu l$  of whole blood.

\* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum

emission of 787 nm.

Application Notes:

The DX9 antibody reacts with the KIR (killer cell inhibitory recentor)


(killer cell inhibitory receptor) designated NKB1 or KIR3DL1.

Additional reported applications (for

the relevant formats) include:

immunoprecipitation<sup>1</sup> and restoring the NK cell cytotoxicity<sup>4,8</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for

functional assays (Cat. No. 312710).



## Application References:

- 1. Litwin V, et al. 1994. J. Exp. Med. 180:537. (IP)
- 2. Gumperz J, et al. 1996. J. Exp. Med. 183:1817.
- 3. Gardiner CM, et al. 2001. J. Immunol. 166:2992.
- 4. Bakker ABH, et al. 1998. J. Immunol. 160:5239.
- 5. Goodier M, et al. 2000. J. Immunol. 165:139.
- 6. Kirwan SE and Burshtyn DN. 2005. J. Immunol. 175:5006. (FC)
- 7. Yawata M, et al. 2002. Immunogenetics 54:543.
- 8. Valiante NM, et al. 1997. Immunity 7:739.
- 9. Pascal V, et al. 2007. J. Immunol. 179:1625. (FC) PubMed
- 10. Lichterfeld M, et al. 2008. J. Exp. Med. 204:2813. (FC) PubMed
- 11. Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed
- 12. Purdy AK, et al. 2014. J Immunol. 193:4675. PubMed

#### **Description:**

CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.

# Antigen References:

- 1. Colonna M, et al. 1995. Science 268:405.
- 2. D'Andrea A, et al. 1995. J. Immunol.. 155:2306.
- 3. Uhrburg M, et al. 1997. Immunity 7:753.
- 4. Gumperz JE, et al. 1996. J. Exp. Med. 183:1817.
- 5. Wagtmann N, et al. 1995. Immunity 3:801.